Credit: Shutterstock
December 11, 2024 07:00 AM EST
Deals
Bioregnum
R&D
China
Pharma
FDA+

The End­points 100: The biotech in­dus­try braces for Trump 2.0

John Carroll

Editor & Founder

Big changes are afoot at the FDA in the wake of Don­ald Trump’s re­elec­tion, and there’s con­sid­er­able anx­i­ety in se­nior biotech ranks that an up­heaval …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times